Biogen LEQEMBI Approval: Stock Plunges 8% Despite FDA Greenlight
Can Biogen’s revolutionary new Alzheimer’s treatments save the company’s valuation, or is the massive market sell-off a warning sign for investors? Maik Kemper Editor in Chief What does…